Any current/future capex/capital investment/strategic investment?

Incremental Capex focus areas: machinery, plant & equipment; infrastructure (building); and instrumentation. FY23 Capex mainly on instrumentation to support expansion into Indonesia, Latin America, Malaysia, and India. Minimal machinery replacement, e.g., $50-60K for X-ray templating machine. No plans for full automation due to high cost; current 80-85% capacity utilization can support 5-year strategic growth. Space available in El Dorado Hills facility for future machines and warehouse optimization. Investment of ₹100 crore in subsidiary Mars Medical via preferential shares to support implant

Future growth expectations in sales/revenue/volumes?

Implant business expects 50-70% growth compared to the current year (Page 15). Hospital business grew about 20% in FY23 and is projected to continue at 15-20% growth next year (Page 11). Sales volume growth seen as much higher compared to previous years, with FY23 India sales being 3x that of FY22, volumes possibly 5x (Page 16). US implant business aims to become a USD 100 million business in 5 years with 60% revenue from the US, 40% outside (Page 6). For the SOC (Surgical Operating Center) model, revenues expected to improve as new units mature and mature existing units increase surgeries (Pa

Future growth expectations in earnings/operating earnings/profits/EPS?

Hospital business expected to grow at 20-25% over the next 2-3 years as occupancy increases and expansion occurs. Implant business aims to achieve USD 100 million in revenue within 5 years with a 20%+ EBITDA margin. For FY23, hospital revenue grew 10% to Rs. 728 crore; EBITDA grew 13% to Rs. 161 crore; PAT margin stood at 11%. Consolidated EBITDA margin expected to be around 17-20% with margin expansion due to operating leverage. US implant business has grown over 3-fold in FY23 with EBITDA positive; projected to have healthy margins going forward. Company targets being operational expenses ne

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in numeric or summarized terms. Vishal inquires about the number of contracts won and lost, indicating active contract management. Sushobhan mentions that one annual contract was lost in the mid-western state, but they have won a couple of contracts recently. The lost contract involves a centralized contract with multiple hospitals, allowing for partial mitigation through local purchases. Most contracts are annual, with some lasting up to 3 years. There is an ongoing effort to reinstate lost busines

ShalbyQ4 FY23Healthcare Services

Shalby Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹145P/E: 39.8Market Cap: ₹1.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Implant business expects 50-70% growth compared to the current year (Page 15).
Hospital business grew about 20% in FY23 and is projected to continue at 15-20% growth next year (Page 11).
Sales volume growth seen as much higher compared to previous years, with FY23 India sales being 3x that of FY22, volumes possibly 5x (Page 16).
US implant business aims to become a USD 100 million business in 5 years with 60% revenue from the US, 40% outside (Page 6).
For the SOC (Surgical Operating Center) model, revenues expected to improve as new units mature and mature existing units increase surgeries (Page 18).
Target to achieve single-digit positive margins and 15% return on capital employed over the coming years (Pages 17-18).

Margin guidance

Category 3

Hospital business expected to grow at 20-25% over the next 2-3 years as occupancy increases and expansion occurs.
Implant business aims to achieve USD 100 million in revenue within 5 years with a 20%+ EBITDA margin.
For FY23, hospital revenue grew 10% to Rs. 728 crore; EBITDA grew 13% to Rs. 161 crore; PAT margin stood at 11%.
Consolidated EBITDA margin expected to be around 17-20% with margin expansion due to operating leverage.
US implant business has grown over 3-fold in FY23 with EBITDA positive; projected to have healthy margins going forward.
Company targets being operational expenses neutral in implant business this fiscal year.
Expect single-digit positive EBITDA for implant business in near term.
Overall guidance includes strong double-digit growth in hospital business and margin improvements.

See what Shalby management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

- A significant portion of recent fundraising was used primarily to repay existing loan facilities, with a smaller part allocated to working capital requirements. (Page 22) - There is an existing investment of around INR 100 crore into the subsidiary Mars Medical through preferential shares, indicating equity infusion. (Page 21) - The company maintains a low gearing ratio (0.03x at standalone level and 0.15x at group level), indicating a strong balance sheet with limited reliance on debt. (Page 6 and 5) - No explicit mention of plans for new debt or equity fundraising in the near future; current focus appears to be on managing working capital and repaying existing debt. (Page 22) - Capex plans exist but primarily focused on utilizing idle capacity and modest incremental spending rather than large new financing. (Page 20-21) In summary, no new significant fundraising through debt or equity was disclosed beyond managing existing liabilities and strategic investments.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in numeric or summarized terms.
Vishal inquires about the number of contracts won and lost, indicating active contract management.
Sushobhan mentions that one annual contract was lost in the mid-western state, but they have won a couple of contracts recently.
The lost contract involves a centralized contract with multiple hospitals, allowing for partial mitigation through local purchases.
Most contracts are annual, with some lasting up to 3 years.
There is an ongoing effort to reinstate lost business and acquire new contracts, showing optimism for future order inflows.
No specific figures regarding total order book size or pending orders are disclosed in the provided pages.

See what Shalby management said on order book — free account, 30 seconds.

Capex plans

Yes

Incremental Capex focus areas: machinery, plant & equipment; infrastructure (building); and instrumentation.
FY23 Capex mainly on instrumentation to support expansion into Indonesia, Latin America, Malaysia, and India.
Minimal machinery replacement, e.g., $50-60K for X-ray templating machine.
No plans for full automation due to high cost; current 80-85% capacity utilization can support 5-year strategic growth.
Space available in El Dorado Hills facility for future machines and warehouse optimization.
Investment of ₹100 crore in subsidiary Mars Medical via preferential shares to support implant business growth.
Ongoing need for continuous investment in surgical instruments (due to wear and metal fatigue) integral to implants business.
Company envisions reaching $100 million business in 5 years with over 20% EBITDA margin, backed by strategic leadership team buildup.

Track Shalby — get its next earnings analysis in your feed

Margin guidance

Category 3

Hospital business expected to grow at 20-25% over the next 2-3 years as occupancy increases and expansion occurs.
Implant business aims to achieve USD 100 million in revenue within 5 years with a 20%+ EBITDA margin.
For FY23, hospital revenue grew 10% to Rs. 728 crore; EBITDA grew 13% to Rs. 161 crore; PAT margin stood at 11%.
Consolidated EBITDA margin expected to be around 17-20% with margin expansion due to operating leverage.
US implant business has grown over 3-fold in FY23 with EBITDA positive; projected to have healthy margins going forward.
Company targets being operational expenses neutral in implant business this fiscal year.
Expect single-digit positive EBITDA for implant business in near term.
Overall guidance includes strong double-digit growth in hospital business and margin improvements.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in numeric or summarized terms.
Vishal inquires about the number of contracts won and lost, indicating active contract management.
Sushobhan mentions that one annual contract was lost in the mid-western state, but they have won a couple of contracts recently.
The lost contract involves a centralized contract with multiple hospitals, allowing for partial mitigation through local purchases.
Most contracts are annual, with some lasting up to 3 years.
There is an ongoing effort to reinstate lost business and acquire new contracts, showing optimism for future order inflows.
No specific figures regarding total order book size or pending orders are disclosed in the provided pages.

How does Shalby rank vs peers in Healthcare Services?

Pro feature

ThisShalby

Rev 3Mar 3

See where Shalby sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Shalby rank in Healthcare Services?

Compare Shalby against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Nephrocare Health Services (Q1 FY27)
International operations contribute around 45% of revenue, reflecting their growing importance in overall growth. Key concall takeaways from Nephrocare Health…

Compare:vs Apollo Hospitals vs Max Healthcare vs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shalby Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Shalby rank in Healthcare Services?

Continue your research

What Shalby's management said in earlier quarters

Others in Healthcare Services this season